In the U.S., we’ve recently seen remarkable progress in developing therapeutics for diseases like Alzheimer’s, where no approved disease-slowing treatments previously existed. While breakthroughs such as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla have led to modest improvements in slowing cognitive decline in Alzheimer’s patients, there remains a need for safer, more effective and more targeted medications that treat the underlying causes of disease.